Terns Pharmaceuticals Inc
TERN5.620USD
+0.150+2.74%
交易中 （美东）报价延迟15分钟
490.61M总市值
亏损市盈率 TTM
关于 Terns Pharmaceuticals Inc 公司
Terns Pharmaceuticals, Inc. 是一家临床阶段生物制药公司。该公司致力于开发一系列小分子候选产品，以治疗包括肿瘤和肥胖在内的严重疾病。其产品线包括三个临床阶段开发项目：TERN-701、TERN-601 和 TERN-501。TERN-701 是口服强效变构 BCR-ABL 酪氨酸激酶抑制剂 (TKI)，专门针对慢性粒细胞白血病 (CML) 的 ABL 肉豆蔻酰基口袋，慢性粒细胞白血病是一种始于骨髓并导致白血病细胞生长的癌症。TERN-601 是一种小分子胰高血糖素样肽-1 受体 (GLP-1R) 激动剂，旨在口服用于治疗肥胖症和其他代谢疾病。TERN-501 是一种甲状腺激素受体 β (THR-b) 激动剂，具有高代谢稳定性和肝脏分布。该公司还专注于开发用于治疗肥胖症的TERN-800系列小分子葡萄糖依赖性胰岛素促泌多肽受体（GIPR）调节剂。
公司简介
公司代码TERN
公司名称Terns Pharmaceuticals Inc
上市日期Feb 05, 2021
CEOMs. Amy L. Burroughs
员工数量59
证券类型Ordinary Share
年结日Feb 05
公司地址1065 East Hillsdale Blvd., Suite 100
城市FOSTER CITY
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94404
电话16505255535
网址https://ternspharma.com/
公司代码TERN
上市日期Feb 05, 2021
CEOMs. Amy L. Burroughs
公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Jill M. Quigley, J.D.
Ms. Jill M. Quigley, J.D.
Independent Director
Independent Director
--
--
Dr. Radhika Tripuraneni, M.D.
Dr. Radhika Tripuraneni, M.D.
Independent Director
Independent Director
--
--
Ms. Sun (Melita) Jung
Ms. Sun (Melita) Jung
Chief Business Officer
Chief Business Officer
--
--
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
--
--
Mr. David Fellows
Mr. David Fellows
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Hongbo Lu, Ph.D.
Ms. Hongbo Lu, Ph.D.
Independent Director
Independent Director
--
--
Dr. Emil T. Kuriakose, M.D.
Dr. Emil T. Kuriakose, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Independent Director
Independent Director
--
--
Ms. Amy L. Burroughs
Ms. Amy L. Burroughs
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Andrew W. Gengos
Mr. Andrew W. Gengos
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Jill M. Quigley, J.D.
Ms. Jill M. Quigley, J.D.
Independent Director
Independent Director
--
--
Dr. Radhika Tripuraneni, M.D.
Dr. Radhika Tripuraneni, M.D.
Independent Director
Independent Director
--
--
Ms. Sun (Melita) Jung
Ms. Sun (Melita) Jung
Chief Business Officer
Chief Business Officer
--
--
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
--
--
Mr. David Fellows
Mr. David Fellows
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Hongbo Lu, Ph.D.
Ms. Hongbo Lu, Ph.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Soleus Capital Management, L.P.
9.35%
OrbiMed Advisors, LLC
8.66%
Vivo Capital, LLC
7.90%
Morgan Stanley & Co. LLC
7.05%
Deep Track Capital LP
6.38%
Other
60.66%
持股股东
持股股东
占比
Soleus Capital Management, L.P.
9.35%
OrbiMed Advisors, LLC
8.66%
Vivo Capital, LLC
7.90%
Morgan Stanley & Co. LLC
7.05%
Deep Track Capital LP
6.38%
Other
60.66%
股东类型
持股股东
占比
Hedge Fund
34.01%
Investment Advisor
22.53%
Investment Advisor/Hedge Fund
16.12%
Research Firm
9.80%
Private Equity
8.66%
Venture Capital
8.13%
Sovereign Wealth Fund
0.97%
Individual Investor
0.30%
Bank and Trust
0.13%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
343
88.10M
100.88%
-22.94M
2025Q1
352
90.67M
103.82%
-24.88M
2024Q4
339
91.95M
108.28%
-13.40M
2024Q3
310
84.11M
100.51%
-7.48M
2024Q2
277
70.14M
99.60%
-17.86M
2024Q1
253
68.60M
105.57%
-10.37M
2023Q4
237
68.12M
109.36%
-7.25M
2023Q3
218
65.97M
109.78%
-9.89M
2023Q2
209
62.15M
110.88%
-6.45M
2023Q1
187
57.73M
103.34%
-5.55M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Soleus Capital Management, L.P.
8.17M
9.35%
+24.60K
+0.30%
Mar 31, 2025
OrbiMed Advisors, LLC
7.56M
8.66%
--
--
Mar 31, 2025
Vivo Capital, LLC
6.90M
7.9%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
6.16M
7.05%
+3.87M
+169.24%
Mar 31, 2025
Deep Track Capital LP
5.58M
6.38%
--
--
Apr 14, 2025
BlackRock Institutional Trust Company, N.A.
5.12M
5.86%
-6.44K
-0.13%
Mar 31, 2025
The Vanguard Group, Inc.
4.15M
4.75%
+282.57K
+7.30%
Mar 31, 2025
Citadel Advisors LLC
3.91M
4.47%
+640.11K
+19.59%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
3.84M
4.4%
-906.64K
-19.08%
Mar 31, 2025
Candriam Luxembourg S.A.
2.88M
3.29%
+214.35K
+8.06%
May 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Roundhill GLP-1 & Weight Loss ETF
2.57%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
ALPS Medical Breakthroughs ETF
0.22%
iShares Micro-Cap ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
Avantis US Small Cap Equity ETF
0.03%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
查看更多
Roundhill GLP-1 & Weight Loss ETF
占比2.57%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.85%
ALPS Medical Breakthroughs ETF
占比0.22%
iShares Micro-Cap ETF
占比0.06%
ProShares Ultra Nasdaq Biotechnology
占比0.04%
Invesco Nasdaq Biotechnology ETF
占比0.04%
Avantis US Small Cap Equity ETF
占比0.03%
iShares Biotechnology ETF
占比0.03%
iShares Russell 2000 Value ETF
占比0.02%
Invesco RAFI US 1500 Small-Mid ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
